SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $448 | -28.1% | 30,825 | +3.6% | 0.00% | 0.0% |
| Q2 2023 | $623 | -0.6% | 29,745 | +0.2% | 0.00% | 0.0% |
| Q1 2023 | $627 | -34.1% | 29,685 | -20.6% | 0.00% | 0.0% |
| Q4 2022 | $951 | -99.9% | 37,374 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $898,000 | +32.8% | 37,362 | +6.3% | 0.00% | 0.0% |
| Q2 2022 | $676,000 | +20.1% | 35,148 | +8.5% | 0.00% | 0.0% |
| Q1 2022 | $563,000 | -20.6% | 32,394 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $709,000 | +14.4% | 32,371 | -0.3% | 0.00% | 0.0% |
| Q3 2021 | $620,000 | -6.8% | 32,465 | -16.2% | 0.00% | 0.0% |
| Q2 2021 | $665,000 | +20.5% | 38,751 | +56.9% | 0.00% | 0.0% |
| Q1 2021 | $552,000 | +0.5% | 24,700 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $549,000 | +50.4% | 24,700 | 0.0% | 0.00% | – |
| Q3 2020 | $365,000 | -0.3% | 24,700 | 0.0% | 0.00% | – |
| Q2 2020 | $366,000 | +83.9% | 24,700 | +36.5% | 0.00% | – |
| Q1 2020 | $199,000 | +25.2% | 18,100 | 0.0% | 0.00% | – |
| Q4 2019 | $159,000 | +3.9% | 18,100 | -11.7% | 0.00% | – |
| Q3 2019 | $153,000 | -19.9% | 20,500 | 0.0% | 0.00% | – |
| Q2 2019 | $191,000 | +289.8% | 20,500 | +118.1% | 0.00% | – |
| Q1 2019 | $49,000 | +16.7% | 9,400 | 0.0% | 0.00% | – |
| Q4 2018 | $42,000 | -44.7% | 9,400 | 0.0% | 0.00% | – |
| Q3 2018 | $76,000 | +15.2% | 9,400 | 0.0% | 0.00% | – |
| Q2 2018 | $66,000 | -50.7% | 9,400 | 0.0% | 0.00% | – |
| Q1 2018 | $134,000 | +63.4% | 9,400 | 0.0% | 0.00% | – |
| Q4 2017 | $82,000 | -25.5% | 9,400 | 0.0% | 0.00% | – |
| Q3 2017 | $110,000 | -16.0% | 9,400 | 0.0% | 0.00% | – |
| Q2 2017 | $131,000 | +424.0% | 9,400 | +421.9% | 0.00% | – |
| Q1 2017 | $25,000 | +92.3% | 1,801 | +0.1% | 0.00% | – |
| Q4 2016 | $13,000 | -51.9% | 1,800 | 0.0% | 0.00% | – |
| Q3 2016 | $27,000 | -75.2% | 1,800 | -83.8% | 0.00% | – |
| Q2 2016 | $109,000 | – | 11,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |